Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology.
Department of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology Southeast University, Nanjing, China.
Bosn J Basic Med Sci. 2021 Apr 1;21(2):246-251. doi: 10.17305/bjbms.2020.5106.
Most acute promyelocytic leukemia (APL) are characterized by reciprocal translocations t(15;17)(q22;21), which results in the fusion of PML gene at 15q22 with RARα gene at 17q21. However, several complex variant translocations also have been reported. Here we report a 62-year-old man with typical morphology and clinical features of APL with a complex karyotype including add(11)(p15) and t(13,20)(q12;q11.2) without typical t(15;17) assayed by the G-banding analysis. FISH with a PML/RARα dual-color DNA probe showed an atypical fusion signal, RT-qPCR analysis showed PML/RARα fusion transcripts, and NGS detected FLT3, WT1, and KRAS mutations. The patient achieved complete remission after treatment with conventional chemotherapy combined ATRA and ATO. Although the mechanism of this kind of cryptic variant remains unknown, we conclude that the cryptic PML/RARα fusion with add(11)(p15), t(13,20)(q12;q11.2) seems not to alter the effectiveness of chemotherapy combined with ATRA and ATO.
大多数急性早幼粒细胞白血病(APL)的特征是存在相互易位 t(15;17)(q22;21),这导致 15q22 上的 PML 基因与 17q21 上的 RARα 基因融合。然而,也已经报道了几种复杂的变体易位。在这里,我们报告了一例 62 岁男性,具有典型形态学和 APL 的临床特征,具有复杂的核型,包括 add(11)(p15)和 t(13,20)(q12;q11.2),而典型的 t(15;17)未通过 G 带分析检测到。使用 PML/RARα 双色 DNA 探针进行 FISH 显示非典型融合信号,RT-qPCR 分析显示 PML/RARα 融合转录本,NGS 检测到 FLT3、WT1 和 KRAS 突变。该患者在接受常规化疗联合 ATRA 和 ATO 治疗后达到完全缓解。尽管这种隐匿性变异的机制尚不清楚,但我们得出结论,隐匿性 PML/RARα 融合与 add(11)(p15)、t(13,20)(q12;q11.2)似乎不会改变化疗联合 ATRA 和 ATO 的疗效。